Oncotarget

Research Papers:

Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer

Xin Qian, Jia Liu, Yuhui Sun, Meifang Wang, Huaiding Lei, Guoshi Luo, Xianjun Liu, Chang Xiong, Dan Liu, Jie Liu and Yijun Tang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:29154-29165. https://doi.org/10.18632/oncotarget.8684

Metrics: PDF 1370 views  |   HTML 1478 views  |   ?  


Abstract

Xin Qian1,2,*, Jia Liu3,*, Yuhui Sun4,*, Meifang Wang1,2, Huaiding Lei1,2, Guoshi Luo1,2, Xianjun Liu1,2, Chang Xiong1,2, Dan Liu1,2, Jie Liu1,2, Yijun Tang1,2

1Department of Respiratory Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, P.R. China

2Institute of Respiratory Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, P.R. China

3Department of Orthopedic, Lanzhou University First Hospital, Lanzhou, 730000, Gansu, P.R. China

4Department of Emergency Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, P.R. China

*These authors contributed equally to this work

Correspondence to:

Yijun Tang, e-mail: tangyijun_799@163.com

Keywords: circulating cell-free DNA, non-small cell lung cancer, sensitivity, specificity, epidermal growth factor receptor

Received: October 29, 2015     Accepted: March 28, 2016     Published: April 11, 2016

ABSTRACT

Detection of an epidermal growth factor receptor (EGFR) mutation in circulating cell-free DNA (cfDNA) is a noninvasive method to collect genetic information to guide treatment of lung cancer with tyrosine-kinase inhibitors (TKIs). However, the association between cfDNA and detection of EGFR mutations in tumor tissue remains unclear. Here, a meta-analysis was performed to determine whether cfDNA could serve as a substitute for tissue specimens for the detection of EGFR mutations. The pooled sensitivity, specificity, and areas under the curve of cfDNA were 0.60, 0.94, and 0.9208 for the detection of EGFR mutations, 0.64, 0.99, and 0.9583 for detection of the exon 19 deletion, and 0.57, 0.99, and 0.9605 for the detection of the L858R mutation, respectively. Our results showed that cfDNA has a high degree of specificity to detect exon 19 deletions and L858R mutation. Due to its high specificity and noninvasive characteristics, cfDNA analysis presents a promising method to screen for mutations in NSCLC and predict patient response to EGFR-TKI treatment, dynamically assess treatment outcome, and facilitate early detection of resistance mutations.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 8684